UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

~~February~~March 2012, 2026

Date of Report (Date of earliest event reported)

Advanced Biomed Inc.

(Exact name of Company as specified in its charter)

Nevada	001-42548	87-2177170
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification Number)

No. 689-85 Xiaodong Road, Yongkang District

Tainan City, Taiwan

(Address of principal executive offices)

886-6-3121716

(Registrant’s telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		ADVB		The Nasdaq Stock Market LLC

Item 38.0301 ~~Material~~Other ~~Modifications to Rights of Security Holders.~~Event

ToAs previously disclosed, on July 18, 2025, Advanced Biomed Inc. (the ~~extent~~“Company”) received a written notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ~~required~~(“Nasdaq” byor ~~Item~~the 3“Staff”) notifying the Company that the bid price for the Company’s common stock had closed below the minimum $1.~~03,~~00 per share requirement for continued listing on the ~~disclosure~~Nasdaq ~~set~~Capital ~~forth~~Market inunder ~~Item~~Nasdaq 5Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).03 isIn ~~incorporated~~accordance ~~herein~~with byNasdaq ~~reference~~Listing Rule 5810(c)(3)(A), the Company was provided a compliance period of 180 calendar days, or until January 14, 2026, to regain compliance with the Minimum Bid Price Requirement.

~~Item~~The 5Company did not regain compliance with the Minimum Bid Price Requirement by January 14, 2026.03 ~~Amendments~~Accordingly, toby ~~Articles~~letter dated January 16, 2026, the Staff notified the Company that its securities would be scheduled for delisting from Nasdaq and suspended at the opening of ~~Incorporation~~business oron ~~Bylaws;~~January ~~Change~~27, in2026, ~~Fiscal~~unless ~~Year~~the Company requested an appeal of this determination before a Nasdaq Listing Qualifications Hearings Department (the “Panel”).

On ~~February~~ 3January 21, 2026, ~~Advanced Biomed Inc. (~~the “Company”) ~~filed~~appealed ~~with~~ the Staff’s ~~Secretary~~delisting ofdetermination ~~State~~by ofsubmitting ~~the~~a ~~State~~hearing ofrequest ~~Nevada~~to ~~an amendment (~~the ~~“Certificate~~Panel, ofwhich ~~Amendment”)~~stayed tothe ~~its~~suspension ~~amended and restated certificate~~ of ~~incorporation, as amended (~~the ~~“Certificate~~Company’s ofsecurities ~~Incorporation”),~~and tothe ~~effect~~filing of a ~~reverse~~Form ~~stock~~25-NSE ~~split~~pending of the ~~Company~~Panel’s ~~common~~decision. ~~stock,~~A ~~par~~hearing ~~value~~was ~~$0.001~~held ~~per~~on ~~share~~February ~~(the “Common Stock”)~~17, at2026. aThe ~~ratio~~Company ofpresented to ~~1-for-20 (~~the ~~“Reverse~~Panel ~~Stock~~a ~~Split”).~~plan ~~The~~to ~~Company’s~~regain ~~Common~~compliance ~~Stock~~with ~~began~~the ~~trading~~Minimum onBid aPrice ~~post-split basis~~Requirement, atincluding the ~~open~~implementation of ~~trading~~a onreverse ~~The~~stock ~~Nasdaq~~split approved ~~Capital~~by ~~Market~~the Company’s stockholders on ~~February~~January 2012, 2026 ~~(the “Effective Time”)~~.

~~At the~~On ~~Effective~~March ~~Time~~12, ~~every~~2026, ~~twenty (20) shares of~~ the Company’s ~~issued~~received ~~and~~a ~~outstanding Common Stock were automatically converted into~~written ~~one~~decision ~~(1)~~from ~~share~~the ofPanel ~~Common~~stating ~~Stock,~~that ~~without any change to~~ the ~~par~~Company ~~value~~had ~~per~~regained ~~share.~~compliance Nowith ~~change~~Nasdaq ~~was~~Listing ~~made~~Rule to5550(a)(2). ~~the~~The ~~number~~Panel ofdetermined ~~shares of Common Stock~~that, ~~authorized~~following ~~under~~ the ~~Certificate~~Company’s ofreverse ~~Incorporation.~~stock Nosplit ~~fractional~~completed ~~shares~~on ~~were~~February ~~issued~~20, in2026, ~~connection with~~ the ~~Reverse~~Company ~~Stock~~had ~~Split.~~maintained ~~Stockholders of~~a ~~record~~closing ~~who~~bid ~~otherwise~~price ~~would~~of ~~have~~$1.00 or ~~been~~more ~~entitled~~per toshare, ~~receive~~and ~~fractional~~therefore ~~shares~~the ~~because~~Company ~~they~~is ~~held~~in acompliance ~~number~~with ~~of shares not evenly divisible by~~ the ~~Reverse~~Minimum ~~Stock~~Bid ~~Split~~Price ~~ratio~~Requirement. ~~were~~As ~~automatically entitled to receive an additional fraction of~~ a ~~share~~result, ofthe ~~Common Stock to round up~~Company’s tocommon ~~the~~stock ~~next~~will ~~whole~~remain ~~share.~~listed ~~With~~on ~~respect~~The toNasdaq ~~outstanding shares of Common~~ Stock ~~held~~Market, insubject ~~“street~~to ~~name” through~~ a ~~bank,~~one-year ~~broker~~Panel ~~or other~~monitor ~~nominee,~~pursuant ~~fractional~~to ~~shares~~Nasdaq ~~were~~Listing ~~rounded~~Rule ~~up at the participant level~~5815(d)(4)(A). ~~No cash was paid in lieu of fractional shares.~~

Following the Reverse Stock Split, the shares of Common Stock continue to trade on The Nasdaq Capital Market under the symbol “ADVB.” The new CUSIP number for the Common Stock following the Reverse Stock Split is 00752P203.1

The foregoing summary of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.SIGNATURES

~~Item~~Pursuant ~~8.01~~to ~~Other~~the ~~Information~~requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

On February 18, 2026, the Company issued a press release announcing the Reverse Stock Split. The press release is filed as Exhibit 99.1 and incorporated herein by reference.

	Advanced Biomed Inc.

Date: March 16, 2026	By:	/s/ Yi Lu
		Yi Lu
		Chief Executive Officer

~~Item 9.01 Financial Statement and Exhibits.~~2

Exhibit No.		Description
3.1		Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Advanced Biomed Inc.
99.1		Press Release issued by Advanced Biomed Inc., dated February 18, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Advanced Biomed Inc.
Date: February 26, 2026	By:	/s/ Yi Lu
		Yi Lu
		Chief Executive Officer

Filing Compare · Advanced Biomed Inc.